Drug Profile


Alternative Names: COTI-2

Latest Information Update: 24 Mar 2016

Price : $50

At a glance

  • Originator Critical Outcome Technologies
  • Developer Critical Outcome Technologies; University of Texas M. D. Anderson Cancer Center
  • Class Small molecules; Thiosemicarbazones
  • Mechanism of Action Apoptosis stimulants; Cyclin-dependent kinase modulators; Iron chelating agents; Methylenetetrahydrofolate reductase modulators; P53 gene modulators; Proto oncogene protein c-akt inhibitors; Thymidylate synthase modulators; Tubulin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cervical cancer; Endometrial cancer; Ovarian cancer
  • Preclinical Acute myeloid leukaemia; Cancer; Head and neck cancer; Li-Fraumeni syndrome
  • Research Colorectal cancer

Most Recent Events

  • 17 Feb 2016 Critical Outcome Technologies plans a phase I trial for Acute myeloid leukaemia in USA
  • 17 Feb 2016 Critical Outcome Technologies plans a phase I trial for Li-Fraumeni syndrome in USA
  • 10 Dec 2015 Critical Outcome Technologies and University of Texas MD Anderson Cancer Center sign Clinical Trial Agreement for phase I development of COTI 2
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top